TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease
Pharmacogenetics and Genomics · 2026-07 · 36 (4) · 157-162
DOI: 10.1097/fpc.0000000000000602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenetics and Genomics, online erschienen am 13.04.2026. Verfasst von Mohammed Alkhalifa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine. Hauptthemen laut MEDLINE: Ustekinumab, Inflammatory Bowel Diseases. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objectives
A genome-wide association study identified that genetic variation in the twisted gastrulation protein homolog-1 gene ( TWSG1 rs7242593) was linked to early clinical remission in ustekinumab-exposed patients in the UNITI clinical trials. We aimed to confirm if a single nucleotide variation (SNV) in the TWSG1 gene is associated with clinical remission in inflammatory bowel disease (IBD) patients on ustekinumab.
Methods
A retrospective cohort study was conducted in ustekinumab-treated IBD patients. Participants underwent screening for the TWSG1 SNV rs7242593 and were assessed for clinical disease remission by Harvey–Bradshaw Index or partial Mayo score at 3 and 12 months. Ustekinumab dose and treatment duration were also assessed.
Results
A total of 125 IBD participants were included (wild-type genotype, CC, n = 108; variant genotype, CT, n = 17). Participants in the variant genotype group were more likely to achieve clinical remission at 3 months [odds ratio (OR): 23.11, 95% confidence interval (CI) = 3.92–449.40, adjusted P = 0.0043] and at 12 months (OR = 17.75, 95%CI = 2.42–381.0, adjusted P = 0.016) on standard ustekinumab dosing and less likely to discontinue therapy during the follow-up period (hazard ratio=4.20, 95% CI = 1.94–9.09, P = 0.02). For wild-type carriers, ustekinumab dose escalations were not associated with disease remission at any time.
Conclusion
TWSG1 SNV was associated with early and persistent clinical remission in ustekinumab-exposed IBD patients. Wild-type carriers who did not achieve remission were not rescued with high-dose treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine.
- Division of Clinical Pharmacology and Toxicology, Department of Medicine.
- Department of Physiology and Pharmacology, Western University, London, Ontario, Canada.
Zitieren
APA
Alkhalifa, M., Dela Cruz, G. R., Ponich, T., Gregor, J. C., Yan, B., Khanna, R., McIntosh, K., Beaton, M. D., Kim, R. B., & Wilson, A. (2026). TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease. Pharmacogenetics and Genomics, 36(4), 157-162. https://doi.org/10.1097/fpc.0000000000000602
Vancouver
Alkhalifa M, Dela Cruz GR, Ponich T, Gregor JC, Yan B, Khanna R, et al. TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease. Pharmacogenetics and Genomics. 2026;36(4):157-162. doi:10.1097/fpc.0000000000000602
BibTeX
@article{Alkhalifa2026,
author = {Alkhalifa, Mohammed and Dela Cruz, Gio R and Ponich, Terry and Gregor, James C and Yan, Brian and Khanna, Reena and McIntosh, Keith and Beaton, Melanie D and Kim, Richard B and Wilson, Aze},
title = {TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease},
journal = {Pharmacogenetics and Genomics},
year = {2026},
volume = {36},
number = {4},
pages = {157--162},
doi = {10.1097/fpc.0000000000000602}
}
EUVIMED